The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

Clicks: 4
ID: 303052
1991
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #60 of 220 articles by views in endocrine reviews

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 220 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
LONG-term therapy with somatostatin analogs has been reported to result in the control of hormonal hypersecretion, in improvement of symptomatology, and in tumor shrinkage in patients with acromegaly, endocrine pancreatic tumors, and metastatic carcinoids. One of these somatostatin analogs, octreotide, has been approved for clinical use in most countries, including the United States. It is a well-tolerated, but expensive drug. Experimental studies show that chronic administration of somatostatin analogs causes growth inhibition of a number of (transplantable) tumors in animals, including chondrosarcomas, pancreatic, prostatic, breast, and pituitary cancers. Somatostatin receptors have been demonstrated on a variety of human tumors by classical biochemical binding techniques, as well as by in vitro autoradiography. These tumors include those with amine precursor uptake and decarboxylation (APUD) characteristics (pituitary tumors, endocrine pancreatic tumors, carcinoids, paragangliomas, small cell lung cancers, medullary thyroid carcinomas, pheochromocytomas), as well as meningiomas, well-differentiated brain tumors (astrocytomas), neuroblastomas, and some human breast cancers. Recently we developed a technique that allows the in vivo visualization in man of the somatostatin receptorpositive tumors mentioned above after the iv administration of the 123I-coupled somatostatin analog Tyr3-octreotide. We have simplified, as well as improved, this technique, which should be available for general use in 1992.
Reference Key
openalex_W1998767852 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors STEVEN W. J. LAMBERTS, Eric P. Krenning, Jean–Claude Reubi
Journal endocrine reviews
Year 1991
DOI
10.1210/edrv-12-4-450
URL
https://doi.org/10.1210/edrv-12-4-450
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.